
|Videos|January 28, 2022
What’s New?
Acne patients are benefitting from a robust pipeline with treatments that hold promise for increased efficacy and safety. First-in-class additions to the FDA-approved armamentarium, such as the novel antiandrogen clascoterone (Winlevi; Sun Pharma), give dermatologists and pediatricians new tools to combat this skin condition. Speakers offer insights on matching medications to individual patient needs and controlling costs.
Advertisement
Advertisement
Related to this article

Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.

BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.

GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.

Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.

Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.

HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
2
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
3
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
4
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
5


